Event
Axxam at Discovery on Target 2026 | Boston
Hunter Shaw
Director
BD – East Coast
Axxam will attend Discovery on Target 2026, taking place from September 28 to October 1 in Boston, Massachusetts.
The conference brings together scientists and drug discovery professionals to explore new approaches to target discovery, lead generation, screening technologies, and emerging therapeutic modalities. This makes Discovery on Target an important meeting point for teams working to translate complex target biology into effective drug discovery strategies.
Representing Axxam at the event will be Hunter Shaw, Director, Business Development – East Coast.
From target biology to actionable drug discovery
Identifying a promising therapeutic target is only the beginning. Moving a program forward requires the right combination of biological understanding, robust assays, screening technologies, and data to support confident decisions.
At Axxam, we support drug discovery programs through an integrated approach that connects target identification and validation, assay development, high-throughput screening, hit identification, and compound characterization.
Our scientists combine expertise in molecular and cellular biology with advanced screening and profiling technologies. Depending on the needs of each project, programs can incorporate biochemical and cell-based assays, complex human-relevant cellular models, high-content imaging, electrophysiology, and other complementary readouts.
This flexible approach allows different technologies and biological models to be combined around the specific target and scientific question.
Advanced assays and screening technologies
Discovery programs increasingly involve complex targets and biological mechanisms that cannot always be addressed with a single assay or readout.
Axxam develops and implements fit-for-purpose assays across a broad range of target classes and therapeutic areas. Our capabilities support projects from early target investigation through screening and hit characterization.
These include:
- Biochemical and cell-based assay development
- High-throughput screening (HTS)
- High-content screening and imaging
- Electrophysiology and organellar electrophysiology
- Human iPSC-based and advanced cellular models
- Compound profiling and mechanism-of-action studies
By integrating complementary technologies, we help generate the biological and pharmacological evidence needed to prioritize compounds and guide the next stages of discovery.
Meet Hunter Shaw at Discovery on Target 2026
Hunter Shaw
Director, Business Development – East Coast
If you are attending Discovery on Target in Boston, meet Hunter to discuss your current drug discovery challenges and explore how Axxam’s scientific capabilities can support your program.
Whether you are establishing an assay for a new target, looking for a screening strategy, or exploring more physiologically relevant models, our team can help identify an approach tailored to your research needs.